This site is intended for UK Healthcare professionals only

This site is intended for UK healthcare professionals only

Menu

News

1 Oct, 2021

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3 

Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have not been shown to increase the risk of venous thromboembolism and are safer forms of HRT with respect to the risk for breast cancer, heart disease, heart attack, and stroke.6-8

The idea of using body identical hormones to replace estrogens and to protect the endometrium with progesterone appeals to many women9. These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.1,9

Dr Paula Briggs, incoming Chair of the British Menopause Society, said, “We know women can be concerned about taking hormones and the impact they may have on their health beyond treating menopause symptoms. The availability of a body-identical progesterone which is well tolerated and has a lower risk profile than oral synthetic progestogens, combined with estradiol in a single capsule, is great news for women.  As a healthcare community we should encourage our patients to reconsider the benefits of newer therapeutic options, allowing them to make informed choices.”

Theramex CEO, Robert Stewart, commented, “For many years menopausal women and their healthcare providers have been seeking an EMA approved body-identical combination therapy. The approval of Bijuva® / Bijuve® during Menopause Awareness month represents an important new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms.”

References

1 Theramex 2021, Summary of Product Characteristics

2 FDA Summary Review. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000SumR.pdf. Accessed September 2021.

3 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climateric. 2005;8(Suppl 1):3-63.

4 National Institute for Health and Care Excellence. Menopause: diagnosis and management (NG23). 2015. Available at https://www.nice.org.uk/guidance/ng23/. Accessed September 2021.

5 British Menopause Society. The British Menopause Society & Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. 2016. Available at https://thebms.org.uk/publications/consensus- statements/hormone-replacement-therapy/. Accessed September 2021.

6 Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy. Postgrad Med. 2009;121(1):73–85.

7 Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climateric. 2018;21(4):346-354.

8 Fournier A, Berrine F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103-111.

9 Archer DF, Bernick BA, Mirkin S. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. Expert Rev Clin Pharmacol. 2019;12(8):729–39.

Advertisement

Latest news

Jo’s Cervical Cancer Trust closes

After over two decades, Jo's Cervical Cancer Trust has sadly announced its closure with immediate effect. Founded in 1999, Jo's Cervical Cancer Trust has been at the forefront of cervical cancer awareness, education, and support for those impacted by the disease,...

Endometriosis UK urges women with symptoms to visit GP

Endometriosis UK has urged women with symptoms to visit their GP, following new research, which has shown that 75% would put off going to see a doctor if they were experiencing painful periods which were interfering with day-to-day activities. This figure rises to 92%...

PCWHF Year in Review 2023

Thank you for being part of our wonderful community for another year. Throughout 2023, the Primary Care Women's Health Forum is proud to have supported clinicians across the UK to ensure the very best patient care is delivered. As the year draws to a close, let's take...

NICE publishes updated draft menopause guideline

NICE has published its updated menopause guideline for public consultation. The draft guideline lays out clearly the risks and benefits of taking HRT that can be used to help people when they are discussing whether to start HRT with their clinician. Detailed tables...

Government survey seeks women’s views on reproductive health

Women in England are being encouraged to help shape reproductive health policy by sharing their experiences, in a new government survey. Delivering on a key commitment in the Women’s Health Strategy, the Women’s Reproductive Health Survey seeks women’s views across...